Why Lineage Cell Therapeutics Zoomed Higher Today
Clinical-stage biotech Lineage Cell Therapeutics (NYSEMKT: LCTX) was a bright spot during a dark session for the overall stock market. The company's shares rocketed upward by more than 21% on Monday on news of a collaboration agreement with a large and deep-pocketed partner.
On Monday morning, Lineage disclosed that it and its Cell Cure Neurosciences subsidiary had signed a global collaboration and licensing deal with two units of Swiss healthcare powerhouse Roche Holding (OTC: RHHBY).
Image source: Getty Images.
Source Fool.com
